Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Oncogene

• Publication date

  2006-08-24

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.onc.1209516PMID 16636678
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The membrane targeted apoptosis modulators erucylphosphocholine and erucylphosphohomocholine increase the radiation response of human glioblastoma cell lines in vitro

  2006cited by this paper
• Bid Mediates Apoptotic Synergy between Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) and DNA Damage*

  2005cited by this paper
• Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts

  2005cited by this paper
• Type I and type II reactions in TRAIL-induced apoptosis – results from dose–response studies

  2005cited by this paper
• TRAIL sensitizes for ionizing irradiation-induced apoptosis through an entirely Bax-dependent mitochondrial cell death pathway

  2005cited by this paper
• Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis

  2005influential reference
• Enhanced induction of apoptosis by combined treatment of human carcinoma cells with X rays and death receptor agonists.

  2005cited by this paper
• HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo

  2005cited by this paper
• Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms

  2004cited by this paper
• DNA damage-induced apoptosis

  2004cited by this paper
• Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway

  2004cited by this paper
• The sequential treatment with ionizing radiation followed by TRAIL/Apo-2L reduces tumor growth and induces apoptosis of breast tumor xenografts in nude mice.

  2004cited by this paper
• Cyclic exposure to hypoxia and reoxygenation selects for tumor cells with defects in mitochondrial apoptotic pathways

  2004cited by this paper
• Apoptosis-modulating agents in combination with radiotherapy-current status and outlook.

  2004cited by this paper
• Influence of hypoxia on TRAIL-induced apoptosis in tumor cells.

  2004cited by this paper
• Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.

  2003cited by this paper
• Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy.

  2003cited by this paper
• Many cuts to ruin: a comprehensive update of caspase substrates

  2003cited by this paper
• Death receptor ligands: new strategies for combined treatment with ionizing radiation.

  2003cited by this paper
• Apo2L/TRAIL and its death and decoy receptors

  2003cited by this paper
• Highlights From: 14th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; Frankfurt, Germany November 19–22, 2002

  2003cited by this paper
• Molecular requirements for the combined effects of TRAIL and ionising radiation.

  2003cited by this paper
• Guardians of cell death: the Bcl-2 family proteins.

  2003cited by this paper
• The tyrosine kinase Lck is involved in regulation of mitochondrial apoptosis pathways

  2003cited by this paper
• Intracellular mediators of erucylphosphocholine-induced apoptosis

  2003cited by this paper
• Hypoxia — a key regulatory factor in tumour growth

  2002cited by this paper
• Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo

  2002cited by this paper
• T and B leukemic cell lines exhibit different requirements for cell death: correlation between caspase activation, DFF40/DFF45 expression, DNA fragmentation and apoptosis in T cell lines but not in Burkitt's lymphoma

  2002cited by this paper
• Chemotherapy: targeting the mitochondrial cell death pathway

  2002cited by this paper
• Ionizing radiation can overcome resistance to TRAIL in TRAIL‐resistant cancer cells

  2001cited by this paper
• PUMA, a novel proapoptotic gene, is induced by p53.

  2001cited by this paper
• CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release

  2001cited by this paper
• Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4

  2001cited by this paper
• Bax and Bak Coalesce into Novel Mitochondria-Associated Clusters during Apoptosis

  2001cited by this paper
• Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL

  2001influential reference
• Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death

  2001cited by this paper
• BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak.

  2001cited by this paper
• Role of BAX in the apoptotic response to anticancer agents.

  2000cited by this paper
• Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy.

  2000cited by this paper
• Functional analysis of TRAIL receptors using monoclonal antibodies.

  1999cited by this paper
• Apaf1 and the apoptotic machinery

  1999cited by this paper
• Safety and antitumor activity of recombinant soluble Apo2 ligand.

  1999cited by this paper
• Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo

  1999cited by this paper
• Death by a thousand cuts: an ever increasing list of caspase substrates

  1998cited by this paper
• TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB.

  1997influential reference
• Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway.

  1997influential reference
• Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade.

  1997cited by this paper
• FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex.

  1996cited by this paper
• Tumor suppressor p53 is a direct transcriptional activator of the human bax gene.

  1995cited by this paper
• A time-saving system for irradiations of experimental tumors.

  1994cited by this paper
• Methods for analysis of censored tumor growth delay data.

  1990cited by this paper

• Current approaches overcome the limit of TRAIL-based treatment in colorectal cancer: From fusion protein to nano-delivery platform.

  2025cites this paper
• Ionizing Radiation Increases Death Receptor 5 (DR5)-Mediated Cell Death, but Not Death Receptor 4 (DR4)-Mediated Cell Death in 3D Tumor Spheroids

  2025cites this paper
• Advances in the study of death receptor 5

  2025cites this paper
• Applying Ultrasound to Mechanically and Noninvasively Sensitize Prostate Tumors to TRAIL‐Mediated Apoptosis

  2025cites this paper
• Tumor micro-environment induced TRAIL secretion from engineered macrophages for anti-tumor therapy.

  2024cites this paper
• Cerium oxide nanoparticles display antioxidant and antiapoptotic effects on gamma irradiation‐induced hepatotoxicity

  2024cites this paper
• Celastrol enhances TRAIL‑R2‑mediated apoptosis and cytotoxicity in human renal cell carcinoma cells in caspase‑dependent manner.

  2023cites this paper
• Exosomal delivery of TRAIL and miR-335 for the treatment of hepatocellular carcinoma (Review)

  2022cites this paper
• Programmed cell death, redox imbalance, and cancer therapeutics

  2021cites this paper
• DNA-binding Cell-penetrating Peptide-based TRAIL Over-expression in Adipose Tissue-derived Mesenchymal Stem Cells Inhibits Glioma U251MG Growth

  2021cites this paper
• Chemo-Sensitization of CD133+ Cancer Stem Cell Enhances the Effect of Mesenchymal Stem Cell Expressing TRAIL in Non-Small Cell Lung Cancer Cell Lines

  2021cites this paper
• Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199

  2021cites this paper
• biology Chemo-Sensitization of CD133+ Cancer Stem Cell Enhances the Effect of Mesenchymal Stem Cell Expressing TRAIL in Non-Small Cell Lung Cancer Cell Lines

  2021cites this paper
• Cellular demolition: Proteins as molecular players of programmed cell death.

  2019cites this paper
• High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles enhances DR5 cross-linking and increases antitumor effect against colon cancer

  2018cites this paper
• Mesenchymal Stem Cell Expressing TRAIL as Targeted Therapy against Sensitised Tumour

  2018cites this paper
• Improvement of Pharmacokinetic Profile of TRAIL via Trimer-Tag Enhances its Antitumor Activity in vivo

  2017cites this paper
• University of Groningen Trail receptor-targeted therapy : strategies to enhance DR 4-and DR 5-induced apoptosis

  2017cites this paper
• The paradox role of caspase cascade in ionizing radiation therapy

  2016cites this paper
• High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles enhances DR5 cross-linking and increases antitumour effect against colon cancer.

  2016cites this paper
• Fluorinated dendrimer for TRAIL gene therapy in cancer treatment.

  2016cites this paper
• Targeting Oncoproteins for Molecular Cancer Therapy

  2016cites this paper
• Caudatin induces caspase-dependent apoptosis in human glioma cells with involvement of mitochondrial dysfunction and reactive oxygen species generation

  2016cites this paper
• Targeted therapies for advanced Ewing sarcoma family of tumors.

  2015cites this paper
• Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression

  2015cites this paper
• TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill

  2015cites this paper
• Instability restricts signaling of multiple fibroblast growth factors

  2015cites this paper
• Trail receptor-targeted therapy : strategies to enhance DR4-and DR5-induced apoptosis

  2014cites this paper
• Combination of TRAIL with Bortezomib Shifted Apoptotic Signaling from DR4 to DR5 Death Receptor by Selective Internalization and Degradation of DR4

  2014cites this paper
• Targeting cell death signaling in colorectal cancer: current strategies and future perspectives.

  2014cites this paper
• Trail receptor-targeted therapy : strategies to enhance DR4- and DR5-induced apoptosis

  2014cites this paper
• Two death-inducing human TRAIL receptors to target in cancer: similar or distinct regulation and function?

  2014cites this paper
• PTHrP Overexpression Increases Sensitivity of Breast Cancer Cells to Apo2L/TRAIL

  2013cites this paper
• Manipulating the apoptotic pathway: potential therapeutics for cancer patients.

  2013cites this paper
• Targeting death receptors: is this trail still hot?

  2013cites this paper
• Radiotherapy and TRAIL for cancer therapy.

  2013cites this paper
• Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors.

  2012cites this paper
• Aspirin enhances TRAIL-induced apoptosis via regulation of ERK1/2 activation in human cervical cancer cells.

  2012cites this paper
• Radiation responses and resistance.

  2012cites this paper
• Dacarbazine and the Agonistic TRAIL Receptor-2 Antibody Lexatumumab Induce Synergistic Anticancer Effects in Melanoma

  2012cites this paper
• Development of a radioiodinated apoptosis–inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studies

  2012cites this paper
• Delineation of apoptotic genes for synergistic apoptosis of lexatumumab and anthracyclines in human renal cell carcinoma cells by polymerase chain reaction array

  2012cites this paper
• Efficacy and Mechanistic Evaluation of Tic10, A Novel Antitumor Agent

  2012cites this paper
• Proteasome inhibitor sensitizes oral squamous cell carcinoma cells to TRAIL-mediated apoptosis.

  2011cites this paper
• Enhanced Metastasis Suppression by Targeting TRAIL Receptor 2 in a Murine Model of Triple-Negative Breast Cancer

  2011influential citation
• Emerging antibody combinations in oncology

  2011cites this paper
• Synthetic glycosidated phospholipids induce apoptosis through activation of FADD, caspase-8 and the mitochondrial death pathway

  2011cites this paper
• Apoptosis induction and tumor cell repopulation: The yin and yang of radiotherapy

  2011cites this paper
• Development of new radiopharmaceutical for molecular imaging in oncology

  2011cites this paper
• Combined modality therapy with TRAIL or agonistic death receptor antibodies

  2011cites this paper
• Signalling Pathways Leading to TRAIL Resistance

  2011cites this paper
• Molekular zielgerichtete Tumortherapie durch Eingriffe in die zelluläre Signaltransduktion

  2011cites this paper
• Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction

  2011cites this paper
• Urothelial cancer cell response to combination therapy of gemcitabine and TRAIL.

  2011cites this paper
• TRAIL-Induced Apoptosis Is Preferentially Mediated via TRAIL Receptor 1 in Pancreatic Carcinoma Cells and Profoundly Enhanced by XIAP Inhibitors

  2010cites this paper
• Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-1 and receptor-2 agonists for cancer therapy

  2010cites this paper
• Targeting a Novel N-terminal Epitope of Death Receptor 5 Triggers Tumor Cell Death*

  2010cites this paper
• Molecular targeted therapies for diffuse large B‐cell lymphoma based on apoptosis profiles

  2010cites this paper
• PRO-APOPTOTIC EFFECTS OF APPLE PROCYANIDINS IN HUMAN COLON CANCER CELLS AND THEIR DERIVED METASTATIC CELLS

  2010cites this paper
• Improving the response to molecular targeting of the TRAIL death receptors in colon cancer cells

  2010cites this paper
• Prediction of proapoptotic anticancer therapeutic response based on visualization of death ligand-receptor interaction and specific marker of cellular proliferation

  2010cites this paper
• In vivo Untersuchungen zur Wirksamkeit des agonistischen TRAIL-Rezeptorantikörpers HGS-ETR-2 (Lexatumumab) in Kombination mit ionisierender Strahlung im Nacktmausmodell mit einem Coloncarcinom-Xenograftsystem

  2010cites this paper
• Evolving therapies and FAK inhibitors for the treatment of cancer.

  2010cites this paper
• Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer.

  2010cites this paper
• TRAIL receptor signaling and therapeutics

  2010cites this paper
• Combined treatment with lexatumumab and irradiation leads to strongly increased long term tumour control under normoxic and hypoxic conditions

  2009influential citation
• Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1.

  2009cites this paper
• Apoptosis and colorectal cancer: implications for therapy.

  2009cites this paper
• Apoptosis in Colorectal Tumorigenesis and Chemotherapy

  2009cites this paper
• Effektivität von molekular zielgerichteten Dreifach-Kombinationstherapien

  2009cites this paper
• Targeting death-receptors in radiation therapy.

  2009cites this paper
• Altered regulation of extrinsic apoptosis pathway in HCV‐infected HCC cells enhances susceptibility to mapatumumab‐induced apoptosis

  2009cites this paper
• Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1

  2009cites this paper
• Apoptosis in Carcinogenesis and Chemotherapy

  2009cites this paper
• Efficacy of triple therapies including ionising radiation, agonistic TRAIL antibodies and cisplatin.

  2009cites this paper
• Combined action of celecoxib and ionizing radiation in prostate cancer cells is independent of pro-apoptotic Bax.

  2009cites this paper
• Targeting the tumour stroma to increase efficacy of chemo- and radiotherapy

  2009cites this paper
• Stable XIAP knockdown clones of HCT116 colon cancer cells are more sensitive to TRAIL, taxanes and irradiation in vitro

  2009cites this paper
• Combination of the pro-apoptotic TRAIL-receptor antibody mapatumumab with ionizing radiation strongly increases long-term tumor control under ambient and hypoxic conditions.

  2009cites this paper
• Efficacy of a Triple Treatment with Irradiation, Agonistic TRAIL Receptor Antibodies and EGFR Blockade

  2009cites this paper
• Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism

  2009cites this paper
• TRAIL receptor upregulation and the implication of KRAS/BRAF mutations in human colon cancer tumors

  2009cites this paper
• Emerging drugs for prostate cancer

  2009cites this paper
• Cell survival and apoptosis‐related molecules in cancer cells in effusions: A comprehensive review

  2009cites this paper
• Anti-apoptotic mechanisms of drug resistance in cancer.

  2009cites this paper
• Current status of experimental therapeutics for prostate cancer.

  2008cites this paper
• Targeting TRAIL death receptors.

  2008cites this paper
• Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells.

  2008cites this paper
• A combined approach with rituximab plus anti-TRAIL-R agonistic antibodies for the treatment of haematological malignancies.

  2008cites this paper
• The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway

  2008cites this paper
• The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases

  2008cites this paper
• TRAIL and cancer therapy.

  2008cites this paper
• Molecular targeted agents combined with chemo-radiation in the treatment of locally advanced cervix cancer.

  2008cites this paper
• Apoptosis and non-apoptotic deaths in cancer development and treatment response.

  2008cites this paper
• Mini-review TRAIL and cancer therapy

  2008cites this paper
• Apoptosis Pathways and New Anticancer Agents

  2008cites this paper
• Agents that Regulate DR5 and Sensitivity to TRAIL

  2008cites this paper
• Molekulare Grundlagen der Apoptose

  2008cites this paper
• Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.

  2008cites this paper
• Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3′-untranslated region

  2008cites this paper